Interní Med. 2017; 19(4): 186-190 | DOI: 10.36290/int.2017.033

Fixed-dose combinations – therapy of type 2 diabetes mellitus

MUDr. Eva Račická
Diabetologická a interní ambulance, Ostrava

Diabetes mellitus type 2 is a progressive condition and treatment with single glucose – lowering agent cannot be expected to beeffective in the course of years after diagnosis. Diabetes mellitus is an example of progressive and chronic disease, its pathogenesisis complex with multiple pathophysiological abnormalities. That is the reason for combination therapy. It has been provedpatients adherence to recommended therapy decreases especially with the number of tablets prescribed, frequency of use,duration of treatment and side effects of therapy. Adherence to treatment with two or more drugs is very important for efficacyof combination therapy. Fixed-dose combinations can optimize treatment to achieve good glycemic control without increase innumber of tablets. The article reports summary of current available fixed-dose combinations of oral glucose lowering medications.

Keywords: type 2 diabetes mellitus, adherence, oral glucose, lowering medication, fixed-dose combinations of antidiabetics drugs,
metformin, DPP-4 inhibitors, SGLT2 inhibitors

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Račická E. Fixed-dose combinations – therapy of type 2 diabetes mellitus. Interní Med. 2017;19(4):186-190. doi: 10.36290/int.2017.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. International Diabetes Federation IDF diabetes atlas. 7th ed. 2015 [cited 2015 Dec 9] available from: http://www.diabetesatlas.org.
    2. NZIS-Report ČK/1(09/2016) Stručný přehled činnosti oboru diabetologie a endokrinologie za období 2007-2015, dostupné z www.uzis.cz
    3. Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014; 30: 2415-2422. Go to original source...
    4. Viswanathan M, Golin CE, Jones CD, et al. Medication adherence interventions: comparative effectiveness closing the quality gap:revisiting the state of the science. Evidence Report No. 208.(Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I.) AHRQ Publication No. 12-E010-EF. Rockville (MD): Agency for Healthcare Research and Quality. 2012 Sep [cited 2016 Jul 28]. Available from: https://effectivehealthcare.ahrq.gov/ehc/products/296/1248/EvidenceReport208_CQGMedAdherence_FinalReport_20120905.pdf.
    5. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004; 27(2): 384-391. Go to original source...
    6. Blüher M, Kurz I, Dannenmaier S, et al. Pill burden in patients with type 2 diabetes in Germany: subanalysis from the prospective,noninterventional PROVIL study. Clin Diabetes. 2015; 33: 55-61. Go to original source... Go to PubMed...
    7. Lokhandwala T, Smith N, Sternhufvud C, et al. A retrospective study of persistence, adherence, and health economic outcomes of fixed dose combination vs. loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016; 19: 203-212. Go to original source...
    8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetologia 2015; 58: 429-442. doi: 10.1007/00125-014-3460-0.9. Go to original source... Go to PubMed...
    9. Škrha J, Pelikanova T, Kvapil M. Doporučený postup péče o diabetes mellitus 2. typu, Česká diabetologická společnost, 2017. Dostupné z: http://www.diab.cz.
    10. Blonde L, San Juan ZT. Fixed dose combinations for treatment of type2 diabetes mellitus. Adv Ther 2012; 29: 1-13. Go to original source...
    11. Metformin XR, SPC (Glucophage XR(R)) dostupné z www.sukl.cz
    12. Competact,SPC dostupné z www.sukl.cz
    13. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá fronta 2011.
    14. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: acritical review of head-to-head trials. Diabetes Metab. 2012; 38: 89-101. Go to original source...
    15. Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy withthe fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011; 13: 644-652. Go to original source...
    16. Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012; 14: 565-574. Go to original source...
    17. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009; 11: 611-622. Go to original source...
    18. Kvapil M. Inhibitory SGLT2: nová cesta k léčbě diabetu. V. KvapilM (ed) Diabetologie 2010. Praha, Triton, 2010.
    19. SPC Invokana dostupné z www.sukl.cz
    20. SPC Forxiga dostupné z www.sukl.cz
    21. SPC Jardiance dostupné z www.sukl.cz
    22. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66: 446-456. Go to original source... Go to PubMed...
    23. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382: 941-950. Go to original source...
    24. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56: 2582-2592. Go to original source...
    25. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week,randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014; 37: 1650-1659. Go to original source...
    26. SPC Incresync, dostupné z www.sukl.cz
    27. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015; 38: 394-402. Go to original source...
    28. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015; 38: 384-393. Go to original source...
    29. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015; 38: 376-383. Go to original source...
    30. SPC Glyxambi dostupné z www.sukl.cz
    31. SPC Qtern dostupné z www.sukl.cz

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.